David J. Eckwright, PharmD

Principal Health Outcomes Researcher
Prime Therapeutics LLC

Poster(s):

• (321) Total cost of care (TCOC) and adverse effects (AEs) assessment of bispecific T cell engagers (BiTEs) and Chimeric Antigen Receptor T-Cell (CAR T) therapies for relapsed refractory follicular lymphoma (RRFL)
  Wednesday, October 29, 2025